Optibrium enables collaborative design in its StarDrop platform

NewsGuard 100/100 Score

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the release of StarDrop 7.6, the latest version of its platform for small molecule design, optimisation and analysis. As part of the release, Optibrium introduces a new extension, Idea Tracker, with which medicinal chemists can now easily trace molecular design and optimisation decisions through every step of the complex discovery process, from idea conception to selecting candidates for synthesis.

In a typical drug design journey, whilst information about synthesised compounds is relatively well tracked, information about the genesis and progression of initial ideas is often lacking. Optibrium’s Idea Tracker provides a registration system for ‘virtual’ compounds to bridge this disconnect and enhance workflow efficiency. It facilitates collaboration between team members, both local and remote, providing clear visibility of compound designs and progression across entire discovery projects. This supports better decision-making and prioritisation of synthesis and testing candidates. By linking data for synthesised compounds back to their original designs, iterative improvements can be easily visualised, and future design strategies informed.

To learn more about the Idea Tracker, please visit: https://optibrium.com/project/idea-tracker/ 

Edmund Champness, Chief Scientific Officer at Optibrium: “Drug discovery is not a solo venture, and for fast progress we need to work collaboratively across global teams. Tailored specifically to support collaboration, we are excited to offer the Idea Tracker to our StarDrop customers. Idea Tracker provides a clear picture of compound design processes and optimisation decisions, facilitating efficient discovery workflows. The launch is part of our ongoing mission at Optibrium to innovate and deliver powerful collaborative drug discovery solutions.”

For further information on Optibrium, please visit www.optibrium.com, contact [email protected] or call +44 1223 815900.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New compound shows promise as a more effective treatment for schistosomiasis